tiprankstipranks
Advertisement
Advertisement
Surrozen initiated with an Outperform at LifeSci Capital
PremiumThe FlySurrozen initiated with an Outperform at LifeSci Capital
6M ago
Surrozen, Inc. Reports Significant Q3 2025 Loss
Premium
Company Announcements
Surrozen, Inc. Reports Significant Q3 2025 Loss
6M ago
Surrozen’s Innovative Wnt Pathway Advancements in Retinal Disease Treatment Earns Buy Rating
Premium
Ratings
Surrozen’s Innovative Wnt Pathway Advancements in Retinal Disease Treatment Earns Buy Rating
6M ago
Surrozen’s Innovative Wnt Pathway Approach Garners Buy Rating Amid Promising Preclinical Data
PremiumRatingsSurrozen’s Innovative Wnt Pathway Approach Garners Buy Rating Amid Promising Preclinical Data
9M ago
Surrozen’s Q2 2025: Progress in Eye Disease Therapies
Premium
Company Announcements
Surrozen’s Q2 2025: Progress in Eye Disease Therapies
9M ago
Surrozen files $150M mixed securities shelf
Premium
The Fly
Surrozen files $150M mixed securities shelf
12M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100